


LEGEND-T2DM Evidence Dissemination Summary

Target: **saxagliptin**, Comparator: **dapagliflozin** Outcome: **Acute renal failure**

How Often? (Incidence rates in the PS-matched target cohorts)

Data source	Persons exposed	Person-time (yrs)	Persons with outcome	IR (/1,000 PY)
IQVIA DA Germany	588	615	0	0.00
IQVIA LDP France	-	-	-	-
IQVIA Open Claims	29,907	22,069	240	10.88
Merative CCAE	2,056	1,413	13	9.20
Merative MDCCD	-	-	-	-
Merative MDCR	196	137	<5	<36.51
Optum Clinformatics	2,024	1,509	30	19.89
Optum EHR	2,437	876	17	19.40
Veterans Affairs	-	-	-	-

How Reliable Are the Effect Estimates? (Objective diagnostics)



What have we learned from the OHDSI Network? (Meta-analysis diagnostics and estimate)

